Improvement of Neopharm Bulgaria Ltd management capacity and export potential

Neopharm Bulgaria has been founded in 1996. Till 2002 the company was trading with pharmaceuticals, chemical and other substances at the internal and external markets. We have started our own production in yesr 2003 and our first own product - Neopholic was introduced to the market during the summer of the same year. Our mission is to create superior products that offer therapeutical advantages greatly improving the life of our users when in medical condition for which there aren't any solutions or the existing ones are unsatisfactory. All are developed by our Ramp;D team. Neopharm has been announced as one of the fastest developing companies at the pharmaceutical market related to speed of new products implementation and increase of the annual sales. We constantly invest in new developments and equipment. In order to continue our development and to improve further our market positions we have to increase significantly our management capacity through implementing integrated CRM and ERP system as well as through implementation and certification of a quality management system under ISO9001. Thus we shall improve our in-company organization, shall better plan our production resources and shall have the possibility to analyze the productivity and efficiency through which to optimize our manufacturing and trading activities. The better organization of the overall working process will allow us faster to introduce the envisaged new products into regular production. The certification under the international quality management standard, together with the control equipment that we shall buy under the project, will allow us to further increase our export potential as for most of our partners the availability of such certificate is an obligatory condition for working with us.

Comments
Leave a comment

Overview

Status Closed (completion date)
Start date 13 Mar, 2017
End date 15 Aug, 2018
Contract date 13 Mar, 2017
View in UMIS

Financial information

Total cost 399,200.00
Grant 279,440.00
Self finance 119,760.00
Total paid 277,172.00
EU participation percent 85.0%

Location